Korean J Physiol Pharmacol.  2019 Sep;23(5):393-402. 10.4196/kjpp.2019.23.5.393.

Antitumor profiles and cardiac electrophysiological effects of aurora kinase inhibitor ZM447439

• Lee HA
• Kwon M
• Kim HA
• Kim KS

• KMID: 2455815
• DOI: http://doi.org/10.4196/kjpp.2019.23.5.393

Abstract

Aurora kinases inhibitors, including ZM447439 (ZM), which suppress cell division, have attracted a great deal of attention as potential novel anti-cancer drugs. Several recent studies have confirmed the anti-cancer effects of ZM in various cancer cell lines. However, there have been no studies regarding the cardiac safety of this agent. We performed several cytotoxicity, invasion and migration assays to examine the anti-cancer effects of ZM. To evaluate the potential effects of ZM on cardiac repolarisation, whole-cell patch-clamp experiments were performed with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and cells with heterogeneous cardiac ion channel expression. We also conducted a contractility assay with rat ventricular myocytes to determine the effects of ZM on myocardial contraction and/or relaxation. In tests to determine in vitro efficacy, ZM inhibited the proliferation of A549, H1299 (lung cancer), MCF-7 (breast cancer) and HepG2 (hepatoma) cell lines with ICâ‚…â‚€ in the submicromolar range, and attenuated the invasive and metastatic capacity of A549 cells. In cardiac toxicity testing, ZM did not significantly affect I(Na), I(Ks) or I(K1), but decreased I(hERG) in a dose-dependent manner (ICâ‚…â‚€: 6.53 µM). In action potential (AP) assay using hiPSC-CMs, ZM did not induce any changes in AP parameters up to 3 µM, but it at 10 µM induced prolongation of AP duration. In summary, ZM showed potent broad-spectrum anti-tumor activity, but relatively low levels of cardiac side effects compared to the effective doses to tumor. Therefore, ZM has a potential to be a candidate as an anti-cancer with low cardiac toxicity.

Keyword

Anticancer agents; Aurora kinases inhibitor; Cardiotoxicity; Efficacy testing; ZM447439

MeSH Terms

Action Potentials
Animals
Antineoplastic Agents
Aurora Kinases
Cardiotoxicity
Cell Division
Cell Line
Humans
In Vitro Techniques
Ion Channels
Muscle Cells
Myocardial Contraction
Myocytes, Cardiac
Phosphotransferases*
Rats
Relaxation
Antineoplastic Agents
Ion Channels
Phosphotransferases

Figure

• 

  Fig. 1 Cytotoxicity of ZM447439 (ZM) on human cancer cell lines and normal lung fibroblast. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays were performed with various cancer cell lines—(A) A549 (non-small cell lung cancer), (B) MCF-7 (breast cancer), (C) NCI-H1299 (non-small cell lung cancer), (D) HepG2 (human hepatocellular carcinoma) and (E) HLF (human lung fibroblast) cells—after treatment with ZM at several concentrations (0.01, 0.03, 0.1, 1, 3, and 10 µM). After 24, 48 or 72 h of incubation, cell viability was examined by MTS assay. Data are presented as mean ± standard deviation (n = 3).

• 

  Fig. 2 Invasion assay on ZM447439 (ZM) treated A549 cells. (A) Representative images of the invasiveness of A549 cells that migrated through transwell membranes. Cells were treated with 0.1, 1, and 10 µM ZM for 24, 48, and 72 h. (B) Quantification of the transwell assay by counting the number of invasive cells through the transwell membranes. Data are presented as mean ± standard deviation and compared by ANOVA followed by Dunnett's test (each n = 3). **p < 0.01; ***p < 0.001, compared with vehicle control (VC, 0.1% dimethyl sulfoxide [DMSO] treated cells).

• 

  Fig. 3 Wound healing assay on ZM447439 (ZM) treated A549 cells Wound healing assay was performed to assess the effect of ZM on the migration of A549 cells. (A) The representative images for the cells treated with 0.1% dimethyl sulfoxide (vehicle control, VC) or 10 µM ZM at 0 and 24 hours post-scratch are shown. (B) Quantification of the wound healing assay by migration area and % wound healing of the initial scratch area was compared. Data are presented as mean ± standard deviation and compared by t-test (each n = 3). ***p < 0.001 compared with VC.

• 

  Fig. 4 Effects of ZM447439 (ZM) on action potential (AP) parameters of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). (A) Representative action potential traces of hiPSC-CMs in the absence (control) and presence of 0.3, 1, 3, and 10 µM ZM. (B) Normalized AP parameters of hiPSC-CMs in control (0 µM) and in the presence of 0.3, 1, 3, and 10 µM ZM. Data are expressed as mean ± standard error of the mean and compared by ANOVA followed by Dunnett's test. MDP, maximal diastolic potential; APA, action potential amplitude; dV/dtmax, maximum upstroke velocity; APD50 or APD90, action potential duration at 50% or 90% repolarization. **p < 0.01 compared to control (n = 3).

• 

  Fig. 5 Effects of ZM447439 (ZM) on cardiac ion channel currents. (A) Representative traces demonstrating the effect of ZM on IhERG at doses of 0.3, 1, 3, and 10 µM, respectively (left). Dose-response relationship of ZM showing an IC50 value for IhERG (mean ± standard error of the mean [SEM], n = 4) (right). (B) The representative I–V traces of IhERG in control (left) and in the presence of 10 µM ZM (bottom). I–V relationships of IhERG in the control and 10 µM ZM (mean ± SEM, n = 3) (right). (C–F) Representative traces demonstrating the effect of ZM on IKs (C), IK1 (D), INa (E) and ICa (F) at doses of 10, 30, and 100 µM, respectively (each left) and dose-response relationship of ZM for each ion currents (mean ± SEM, n = 3) (each right).

• 

  Fig. 6 Effects of ZM447439 (ZM) on contraction of rat ventricular myocyte. (A) Representative raw traces of sarcomere shortening and lengthening in the absence (control) and presence of 10 nM, 100 nM, and 1 µM nifedipine. (B) Typical raw traces of sarcomere shortening/lengthening in control and the presence of ZM at concentrations of 100 nM, 1 µM, and 10 µM.

Reference

1. Cirak Y, Furuncuoglu Y, Yapicier O, Aksu A, Cubukcu E. Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis. J BUON. 2015; 20:1414–1419.

2. Zhang Y, Jiang C, Li H, Lv F, Li X, Qian X, Fu L, Xu B, Guo X. Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer. Int J Clin Exp Pathol. 2015; 8:751–757.

3. Zekri A, Lesan V, Ghaffari SH, Tabrizi MH, Modarressi MH. Gene amplification and overexpression of Aurora-C in breast and prostate cancer cell lines. Oncol Res. 2012; 20:241–250.

4. Yang H, Ou CC, Feldman RI, Nicosia SV, Kruk PA, Cheng JQ. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004; 64:463–467.

5. Gavriilidis P, Giakoustidis A, Giakoustidis D. Aurora kinases and potential medical applications of aurora kinase inhibitors: a review. J Clin Med Res. 2015; 7:742–751.

6. Sasai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, Okano Y, Tatsuka M, Suzuki F, Nigg EA, Earnshaw WC, Brinkley WR, Sen S. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton. 2004; 59:249–263.

7. Yan X, Cao L, Li Q, Wu Y, Zhang H, Saiyin H, Liu X, Zhang X, Shi Q, Yu L. Aurora C is directly associated with Survivin and required for cytokinesis. Genes Cells. 2005; 10:617–626.

8. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 2003; 161:267–280.

9. Woo JK, Kang JH, Shin D, Park SH, Kang K, Nho CW, Seong JK, Lee SJ, Oh SH. Daurinol enhances the efficacy of radiotherapy in lung cancer via suppression of aurora kinase A/B expression. Mol Cancer Ther. 2015; 14:1693–1704.

10. Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang YX, Zhang X, Duan W, Yang T, Qiu JX, Zhou SF. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther. 2015; 9:425–464.

11. Min YH, Kim W, Kim JE. The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation. Oncotarget. 2016; 7:84718–84735.

12. Li M, Jung A, Ganswindt U, Marini P, Friedl A, Daniel PT, Lauber K, Jendrossek V, Belka C. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem Pharmacol. 2010; 79:122–129.

13. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007; 7:332–344.

14. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26:5204–5212.

15. Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol. 2008; 10:35–46.

16. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015; 12:547–558.

17. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016; 66:309–325.

18. Peroukides S, Alexopoulos A, Kalofonos H, Papadaki H. Cardiovascular effects of treatment with taxanes. J Cardiovasc Med (Hagerstown). 2012; 13:319–324.

19. Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN, Rogister B. The functional diversity of Aurora kinases: a comprehensive review. Cell Div. 2018; 13:7.

20. Walter AO, Seghezzi W, Korver W, Sheung J, Lees E. The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene. 2000; 19:4906–4916.

21. Margolis RL, Lohez OD, Andreassen PR. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem. 2003; 88:673–683.

22. Sinnecker D, Laugwitz KL, Moretti A. Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing. Pharmacol Ther. 2014; 143:246–252.

23. Lynch S, Pridgeon CS, Duckworth CA, Sharma P, Park BK, Goldring CEP. Stem cell models as an in vitro model for predictive toxicology. Biochem J. 2019; 476:1149–1158.

24. Morgan JP, Morgan KG. Calcium and cardiovascular function. Intracellular calcium levels during contraction and relaxation of mammalian cardiac and vascular smooth muscle as detected with aequorin. Am J Med. 1984; 77(5A):33–46.

25. Bodi I, Mikala G, Koch SE, Akhter SA, Schwartz A. The L-type calcium channel in the heart: the beat goes on. J Clin Invest. 2005; 115:3306–3317.

26. Mladěnka P, Applová L, Patoáka J, Costa VM, Remiao F, Pourová J, Mladěnka A, Karlíčková J, Jahodář L, Vopršalová M, Varner KJ, Štěrba M. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018; 38:1332–1403.

27. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006; 440:463–469.

28. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350:1013–1022.

29. Li Z, Dutta S, Sheng J, Tran PN, Wu W, Chang K, Mdluli T, Strauss DG, Colatsky T. Improving the in silico assessment of proarrhythmia risk by combining hERG (Human Ether-à-go-go-Related Gene) channel-drug binding kinetics and multichannel pharmacology. Circ Arrhythm Electrophysiol. 2017; 10:e004628.

30. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, Giustetto C, Schimpf R, Brugada P, Antzelevitch C. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004; 109:30–35.